Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients

Yang, Min‐Young; Son, Jin‐Hwa; Kim, Gun‐Wook; Kim, Hoon‐Soo; Ko, Hyun‐Chang; Kim, Moon‐Bum; Lim, Kyung Min; Kim, Byung Soo

doi:10.1080/09546634.2018.1527006

Cited by 25 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15][16][17] A recent study by Yang et al demonstrated that up to 46.7% and 16.7% of patients had complete resolution and partial resolution of cutaneous warts, respectively, after the quadrivalent HPV vaccine was administered as the primary treatment for warts, with no statistical difference in treatment response when adjusted for gender, age or duration of disease. 18 Our study further supports an adjunctive role of the quadrivalent HPV vaccine for the treatment for recalcitrant warts that have persisted despite cryotherapy and local treatments. In our study, 30.8% of patients had complete resolution while 34.6% of patients had partial resolution of their cutaneous warts after receiving the HPV vaccine.…”

Section: Discussionsupporting

confidence: 74%

The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Acral Warts: A Retrospective Study

Kuan

Chua

Pan

et al. 2020

Ann Acad Med Singap

View full text Add to dashboard Cite

Introduction: The human papillomavirus (HPV) vaccine has been reported to lead to clinical clearance of lesions when used as an off-label treatment for recalcitrant extragenital warts. The aim of the study is to evaluate the therapeutic and adverse effects of HPV vaccine as an adjunctive therapy for treatment-resistant acral warts. Methods: Patients with persistent warts despite first and second line therapies, and subsequently receiving the quadrivalent HPV vaccine between July 2013 and June 2016 as an adjunctive treatment for recalcitrant warts at the National Skin Centre, were included. Results: Twenty-six patients with a median age of 34 years (range 8 to 77 years) were treated with the HPV vaccine. Nineteen (73.1%) patients completed 3 doses of the vaccine, of whom 5 (26%) achieved complete clearance, 8 (42%) had partial clearance and 6 (32%) did not respond to the vaccine. Among the 4 patients who received 2 doses of the vaccine, 3 (75%) had complete clearance whereas 1 (25%) had partial improvement of their warts. None of the patients reported adverse reactions. Conclusion: Our study suggests a potential adjunctive role of the HPV vaccine in the treatment of acral warts recalcitrant to conventional therapy. Keywords: Acral warts, HPV vaccine, quadrivalent vaccine, recalcitrant warts

show abstract

Section: Discussionsupporting

confidence: 74%

The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Acral Warts: A Retrospective Study

Kuan

Chua

Pan

et al. 2020

Ann Acad Med Singap

View full text Add to dashboard Cite

show abstract

“…Existing wart treatments have low clearance rates and high recurrence rates, and as such, are increasingly seen as non-viable options for recalcitrant infections [17]. Licensed VLP-based HPV vaccines on the market target high-risk oncogenic HPV types, and while studies have reported limited positive responses against anogenital and cutaneous warts, their efficacy is hindered by a lack of specific coverage for verrucae-causing types, namely, HPV types 1, 2, and 3 [57, 58].…”

Section: Discussionmentioning

confidence: 99%

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Toh

Wang

Chung

2021

Preprint

View full text Add to dashboard Cite

Background: Common warts and flat warts are caused by the human papillomavirus (HPV). Peak incidence of wart infection occurs in schoolchildren aged 12-16, where prevalence can be as high as 20%. Traditional treatments aimed at destruction of wart tissue have low clearance rates and high recurrence rates. Occasional reports have even shown warts becoming malignant and progressing into verrucous carcinoma. Current licensed HPV vaccines largely target higher-risk oncogenic HPV types, but do not provide coverage of low-risk types associated with warts. To date, little attention has been given to the development of effective, anti-viral wart treatments. Objective: This study aims to identify immunodominant T-lymphocyte epitopes from the L1 major capsid protein of HPV 1, 2 and 3, a foundational step in bioengineering a peptide-based vaccine for warts. Methods: Cytotoxic T-cell and helper T-cell epitopes were predicted using an array of immunoinformatic tools against a reference panel of frequently observed MHC-I and MHC-II alleles. Predicted peptides were ranked based on IC50 and IFN-γ Inducer Scores, respectively, and top performing epitopes were synthesized and subjected to in vitro screening by IFN-γ enzyme-linked immunosorbent spot assay (ELISpot). Independent trials were conducted using PBMCs of healthy volunteers. Final chosen peptides were fused with flexible GS linkers in silico to design a novel polypeptide vaccine. Results: Seven immunodominant peptides screened from 44 predicted peptides were included in the vaccine design, selected to elicit specific immune responses across MHC class I and class II, and across HPV types. Evaluation of the vaccine′s properties suggest that the vaccine is stable, non-allergenic, and provides near complete global population coverage (>99%). Solubility prediction and rare codon analysis indicate that the DNA sequence encoding the vaccine is suitable for high level expression in Escherichia coli. Conclusions: In sum, this study demonstrates the potential and lays the framework for the development of a peptide-based vaccine against warts.

show abstract

“…D ear E ditor , To the best of our knowledge, 11 reports have described the efficacy of the bivalent human papillomavirus vaccine (BHPV) and quadrivalent human papillomavirus vaccine (QHPV) in the treatment of cutaneous warts . Nine reports described the complete regression of cutaneous warts in all patients treated with BHPV or QHPV (total of 16 cases).…”

Section: Characteristics Of the Study Patientsmentioning

confidence: 99%

“…Abeck and Fölster‐Holst reported that 10 of 16 patients were cured, with younger patients having better cure rates. Furthermore, Yang et al . reported a 47% cure rate in 30 patients.…”

Section: Characteristics Of the Study Patientsmentioning

confidence: 99%

Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: the HPV type may not determine the outcome

Hayashi¹,

Matsumoto²,

Mitsuishi

2019

Br J Dermatol

View full text Add to dashboard Cite

Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients

Cited by 25 publications

References 22 publications

The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Acral Warts: A Retrospective Study

The Quadrivalent Human Papillomavirus Vaccine in Recalcitrant Acral Warts: A Retrospective Study

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: the HPV type may not determine the outcome

Contact Info

Product

Resources

About